References
- Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022341s000approv.pdf . Accessed October 10, 2017
- Taylor PN Baglioni P Liraglutide in weight management N Engl J Med 2015 373 1779 1782
- Available from: http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/OurProducts/PDF/Saxenda_PM_English.pdf . Accessed October 26, 2017
- Pi-Sunyer X Astrup A Fujioka K SCALE Obesity and Prediabetes NN8022-1839 Study Group A randomized, controlled trial of 3.0 mg of liraglutide in weight management N Engl J Med 2015 373 1 11 22 26132939
- Eichholzer M Huang DJ Modlasiak A Impact of body mass index on prognostically relevant breast cancer tumor characteristics Breast Care (Basel) 2013 8 3 192 198 24415969
- Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003780/WC500185788.pdf. Accessed November 14, 2017
- Hicks BM Yin H Yu OH Pollak MN Platt RW Azoulay L Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink BMJ 2016 355 i5340 27797785
- Körner M Stöckli M Waser B Reubi JC GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting J Nucl Med 2007 48 5 736 743 17475961
- Koehler JA Baggio LL Yusta B GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7 Cell Metab 2015 21 3 379 391 25738454
- Tannheimer SL Rehemtulla A Ethier SP Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE Breast Cancer Res 2000 2 4 311 320 11056689
- Larsson SC Mantzoros CS Wolk A Diabetes mellitus and risk of breast cancer: a meta-analysis Int J Cancer 2007 121 4 856 862 17397032
- Hardefeldt PJ Edirimanne S Eslick GD Diabetes increases the risk of breast cancer: a meta-analysis Endocr Relat Cancer 2012 19 6 793 803 23035011
- Neuhouser ML Aragaki AK Prentice RL Overweight, obesity, and postmenopausal invasive breast cancer risk JAMA Oncol 2015 1 5 611 621 26182172
- Lund JL Richardson DB Stürmer T The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application Curr Epidemiol Rep 2015 2 4 221 228 26954351
- D’Agostino RBJr Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group Stat Med 1998 17 19 2265 2281 9802183
- Rubin DB Thomas N Matching using estimated propensity scores: relating theory to practice Biometrics 1996 52 1 249 264 8934595
- Rosenbaum PR Rubin DB The central role of the propensity score in observational studies for causal effects Biometrika 1983 70 1 41 55
- Seeger JD Kurth T Walker AM Use of propensity score technique to account for exposure-related covariates: an example and lesson Med Care 2007 45 10 Suppl 2 S143 S148 17909373
- Schneeweiss S Rassen JA Glynn RJ Avorn J Mogun H Brookhart MA High-dimensional propensity score adjustment in studies of treatment effects using health care claims data Epidemiology 2009 20 4 512 522 19487948
- Parsons LS Reducing bias in a propensity-score matched-pair sample using greedy matching techniques Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference April 22–25, 2001 Cary NC, USA 214 226
- Setoguchi S Solomon DH Glynn RJ Cook EF Levin R Schneeweiss S Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data Cancer Causes Control 2007 18 5 561 569 17447148
- Koroukian SM Cooper GS Rimm AA Ability of Medicaid claims data to identify incident cases of breast cancer in the Ohio Medicaid population Health Serv Res 2003 38 3 947 960 12822920
- Green MS Use of predictive value to adjust relative risk estimates biased by misclassification of outcome status Am J Epidemiol 1983 117 1 98 105 6823958
- Austin PC Type I error rates, coverage of confidence intervals, and variance estimation in propensity-score matched analyses Int J Biostat 2009 5 1 Article 13
- Marso SP Daniels GH Brown-Frandsen K Liraglutide and cardiovascular outcomes in type 2 diabetes N Engl J Med 2016 375 4 311 322 27295427
- Howard J White Paper on Minimum latency and types or categories of cancer World Trade Center Health Program 5 1 2013 Available from: https://www.cdc.gov/wtc/pdfs/policies/wtchpminlatcan-cer2013-05-01-508.pdf Accessed November 14, 2017
- Vogelstein B Kinzler KW The Path to Cancer – Three Strikes and You’re Out N Engl J Med 2015 373 20 1895 1898 26559569
- Nadler DL Zurbenko IG Estimating cancer latency times using a Weibull model Adv Epidemiol 2014 2014 1 1 8